Lilly Partners with Innovent to Develop Cancer Therapies; Expand Partnership; Sintilimab Ex-China Rights Terminated
Executive Summary
Eli Lilly & Co. penned an agreement with Innovent Biologics Inc. to develop at least three new cancer drugs in China over the next ten years.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice